Leo Wealth LLC Raises Holdings in AbbVie Inc. $ABBV

Leo Wealth LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 21.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,388 shares of the company’s stock after purchasing an additional 2,739 shares during the period. Leo Wealth LLC’s holdings in AbbVie were worth $3,516,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the second quarter worth $26,000. Chelsea Counsel Co. acquired a new stake in shares of AbbVie during the third quarter valued at $26,000. Westend Capital Management LLC acquired a new stake in shares of AbbVie during the fourth quarter valued at $29,000. Texas Capital Bancshares Inc TX acquired a new position in AbbVie in the 3rd quarter valued at about $31,000. Finally, Caitlin John LLC acquired a new position in AbbVie in the 3rd quarter valued at about $33,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Down 0.0%

Shares of ABBV opened at $208.79 on Monday. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The firm has a market capitalization of $369.17 billion, a P/E ratio of 88.47, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. The stock’s fifty day simple moving average is $221.58 and its 200 day simple moving average is $224.50.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.25% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. The Goldman Sachs Group restated a “neutral” rating and set a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Citigroup lowered their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. UBS Group cut their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. Finally, Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.